Printer Friendly
The Free Library
22,738,802 articles and books

VNUS Medical Technologies Achieves Two Major Milestones: Blue Cross and Blue Shield Association Recognition of Closure Procedure And New Medicare Pass-Through Device Code for the Closure Catheter.



SAN JOSE, Calif. -- VNUS Medical Technologies announced today that the Blue Cross and Blue Shield Association has drafted for its member Plans a favorable medical policy for the VNUS Closure(R) procedure. In addition the company reported Medicare is establishing a new device category code which will allow hospital outpatient departments to bill for the Closure catheter, effective July 1, 2002.

BCBS BCBS Blue Cross/Blue Shield
BCBS Basel Committee on Banking Supervision
BCBS Barre Center for Buddhist Studies
BCBS Bay City Baptist School
BCBS Bishop Cotton Boys School (Bangalore, India)
BCBS Bar Code Business Software
 Association Coverage Recognition for VNUS Closure Procedure

In establishing its recommendation, the Blue Cross and Blue Shield Association Medical Policy Panel completed a thorough analysis of clinical evidence for the Closure procedure. Brian Farley, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of VNUS Medical Technologies commented, "We are delighted that after careful scientific scrutiny, the BCBSA BCBSA Blue Cross and Blue Shield Association  Medical Policy Panel advised BCBS Plans that the Closure procedure could be considered medically necessary medically necessary Managed care adjective Referring to a covered service or treatment that is absolutely necessary to protect and enhance the health status of a Pt, and could adversely affect the Pt's condition if omitted, in accordance with accepted  as a therapeutic alternative to vein stripping vein stripping Surgery The surgical removal of a varicose vein of the leg by ligating it–eg, the great saphenous vein and its tributaries at the junction with the common femoral vein in the groin, then yanking it, which pops off the collaterals, 'stripping'  surgery for appropriately selected patients. This is the result of the efforts of numerous physicians who have carefully studied and published in prestigious medical journals, the clinical outcomes produced by the VNUS Closure procedure."

Locally operated Blue Cross and Blue Shield member companies around the U.S. now have available to them positive medical policy advice for the Closure procedure, from which the member companies can establish independent policy decisions.

The positive decision by the Blue Cross and Blue Shield Association complements a national coverage policy for the Closure procedure by Aetna/US Healthcare. With positive policies from two of the largest private insurers in the United States, the Closure procedure may now be more accessible than ever to patients.

Medicare Pass-Through Category Code for the Closure Catheter

Medicare has determined that the VNUS Closure (ablation) catheter qualifies as a new medical device under the hospital outpatient prospective payment system and effective July 1, 2002, is establishing a new device category code which will allow hospitals who use the catheter in outpatient treatments for Medicare patients to receive a supplemental pass-through payment for the catheter in addition to the out-patient APC (1) (American Power Conversion Corporation, West Kingston, RI, www.apcc.com) The leading manufacturer of UPS systems and surge suppressors, founded in 1981 by Rodger Dowdell, Neil Rasmussen and Emanual Landsman, three electronic power engineers who had worked at MIT.  payment for the procedure. Under the hospital outpatient prospective payment system, Medicare establishes new device category codes for certain new medical devices that show substantial clinical improvement (as defined by Medicare) compared to currently available treatments, and meet other requirements.

Mr. Farley concluded, "The achievement of these key milestones which together represent a robust independent recognition of the clinical benefits of the Closure procedure are a result of a patient and clinically-oriented focus by VNUS Medical Technologies. We are pleased to see that patients with saphenous vein reflux and painful varicose veins now have greater access to a broadened choice of therapeutic options."

About The Closure Procedure

The Closure procedure involves a thin catheter that is inserted into a diseased vein to controllably heat the vein causing it to collapse and seal as the catheter is slowly withdrawn from the vein. The catheter is connected to a radiofrequency generator that constantly controls the vein temperature to guide effective therapeutic heating and sealing of the vein. The Closure catheter and procedure provides a minimally invasive alternative to vein stripping surgery and has been demonstrated in clinical trials to reduce post-operative pain and recovery time compared to vein stripping surgery. Previously published reports have shown that two years after treatment, 90% of treated legs are free of saphenous saphenous /sa·phe·nous/ (sah-fe´nus) pertaining to or associated with a saphena; applied to certain arteries, nerves, veins, etc.  reflux and symptoms.

About VNUS Medical Technologies, Inc.

VNUS Medical Technologies, founded in 1995, is a privately held company privately held company

A firm whose shares are held within a relatively small circle of owners and are not traded publicly.
 and world leader in the development and commercialization of products for minimally invasive treatment of venous disease. The company currently markets the proprietary Closure System of products for patients who suffer from symptoms associated with venous reflux. The Closure system was cleared for marketing in the U.S. in March 1999. Since then, over 12,000 patients have received the Closure procedure and numerous studies have shown the Closure procedure provides substantial benefits to patients. For more information please visit the company's web site at http://www.vnus.com/.

MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X88406414

Contact: Brian E. Farley, President and Chief Executive Officer of VNUS Medical Technologies, Inc., +1-888-797-vein (8346), or fax, +1-408-944-0292, or bfarley@vnus.com

Website: http://www.vnus.com/
COPYRIGHT 2002 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:VNUS Medical Technologies Achieves Two Major Milestones: Blue Cross and Blue Shield Association Recognition of Closure Procedure And New Medicare Pass-Through Device Code for the Closure Catheter.
Publication:PR Newswire
Geographic Code:1USA
Date:Jun 6, 2002
Words:691
Previous Article:Friends of Long Term Care Join in the First Statewide Grassroots Lobby Day; Staffing Shortage, Skyrocketing Liability Insurance Rates, Reimbursement...
Next Article:Reward Offered: $100,000 For The Ultimate Bleacher Bum.
Topics:



Related Articles
VNUS Medical Technologies, Inc., Announces Hiring of Scott Cramer, Vice President of Sales, Americas.
Blue Cross Reduces Medicare+Choice Premiums; Savings Comes From Federal Increase.
Randomized Trial Shows VNUS(R) Closure(R) System Produces Advantages Over Traditional Vein Stripping for Patients With Symptomatic Varicose Veins And...
VNUS Medical Technologies, Inc. Expands Senior Management Team.
New Trial Shows Varicose Vein Patients Recover Faster After Minimally Invasive Closure(R) Procedure Compared to Vein Stripping Surgery; 'Patient...
VNUS Medical Technologies Launches Closure(R) PLUS - New Catheter for Treatment of Saphenous Vein Reflux and Varicose Veins.
VNUS(R) Medical Technologies Launches VarEx(TM) Instruments for Ambulatory Phlebectomy.
VNUS(R) Medical Technologies Establishes Partnership Agreement to Sell VENOSAN(R) Compression Stockings.
VNUS files venous reflux disease patent infringement lawsuits against AngioDynamics.
Covidien buys VNUS Medical for $440m.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters